Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda

This phase II trial compares the effect of hypofractionated radiotherapy (HFRT) to conventional fractionated radiotherapy (CFRT) when given in combination with cisplatin and brachytherapy in patients with stage IB3, II, or III cervical cancer. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. CFRT delivers the total dose of radiation over the amount of time according to standard practice. HFRT delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. HFRT shortens treatment duration and may reduce costs and may improve the completion rates. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. HFRT may be safe, tolerable, and/or as effective as CFRT when given in combination with cisplatin and brachytherapy in treating patients with stage IB3, II or III cervical cancer.

NCT Number	NCT07276360
Lead Sponsor	Uganda Cancer Institute Collaborators: Varian Medical Systems, Fogarty International Center of the National Institute of Health
Conditions	Cervical Cancer, Cervix Cancer, Cervical Adenocarcinoma, Cervical Small Cell Carcinoma, Cervical Adenosquamous Carcinoma
Enrollment	278 participants
Start Date	2026-03-11
Primary Completion	2028-01-02 (estimated)
Study Completion	2029-01-02 (estimated)
Updated on ClinicalTrials.gov	2026-03-27